Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials

Marketwired - Trials

Last Build Date: Tue, 20 Mar 2018 09:02:04 EDT

Copyright: Copyright: (C) Marketwired

Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery

Tue, 20 Mar 2018 08:30:00 EDT

HOUSTON, TX--(Marketwired - March 20, 2018) - Moleculin Biotech, Inc. (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has entered into a collaboration with a team of scientists in Poland who have received a $300,000 research grant to expand the understanding of how Moleculin's leading STAT3 inhibitor WP1066 and the Company's newly discovered drug candidate, WP1732, create a blockade of transcription factor STAT3 leading to tumor cell death and immune-stimulating effects.

VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101

Mon, 19 Mar 2018 10:17:08 EDT

SOUTH SAN FRANCISCO, CA--(Marketwired - March 19, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. patent application no. 14/762,015 related to oral formulations of AV-101, its new generation glutamatergic product candidate in Phase 2 development for treatment of Major Depressive Disorder (MDD). When issued, the U.S. patent will not expire until at least 2034.

Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia

Wed, 14 Mar 2018 08:00:00 EDT

LAVAL, QUÉBEC--(Marketwired - March 14, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that the first patient has been randomized in the company's TRILOGY Phase 3 program evaluating lead drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), a condition of elevated triglycerides (TGs) in the bloodstream that increases the risk of coronary artery disease and pancreatitis.

VIVUS Reports Fourth Quarter 2017 Financial Results

Tue, 13 Mar 2018 16:05:00 EDT

CAMPBELL, CA--(Marketwired - March 13, 2018) - VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter and year ended December 31, 2017 and provided a business update.